Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Two Pharma JVs Start Operations in China: Hisun-Pfizer and Merck-Simcere

publication date: Sep 13, 2012
Two high-visibility generic drug JVs between east and west pharmas have commenced operations in China. Hisun Pharma and Pfizer have established their $295 million JV to produce branded generic drugs. At the same time, Merck and Simcere teamed up to concentrate on generic drugs for chronic ailments, especially cardiovascular and metabolic disease. Both were announced as letters of intent just over a year ago, and now they have become operational. More details....

Stock Symbols: (SHE: 600267) (NYSE: PFE) (NYSE: MRK) (NYSE SCR)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here